My laboratory recently demonstrated that there is selective expression of phosphoribosomal S6 protein in balloon cells in focal cortical dysplasia and hemimegalencephaly but no expression of the upstream kinase, phospho-p70S6 kinase. Two proteins activated by phospho-p70S6 kinase, phospho-STAT3 and phospho-4EBP1, were not detected in balloon cells. Using complementary DNA arrays in hemimegalencephaly specimens, we found increased expression of cyclin D1 and c-myc messenger ribonucleic acids (RNAs). Expression of cyclin D1 and c-myc genes is transcriptionally activated by βcatenin. Western analysis demonstrated increased levels of nonphosphorylated β-catenin in hemimegalencephalic cortex. Reduced levels of Ser33, Ser37, and Thr41 phospho-β-catenin, sites known to be phosphorylated by glycogen synthase kinase 3 and to be essential for β-catenin inactivation, were detected in hemimegalencephaly. Enhanced transcription of cyclin D1 and c-myc messenger RNAs, increased transcriptionally active β-catenin, and decreased Ser33/Ser37/Thr41 phospho-β-catenin suggest activation of the Wnt-1/β-catenin cascade in hemimegalencephaly, which can lead to aberrant cell proliferation and hemispheric enlargement during brain development. Enhanced activation of phospho-S6 and β-catenin suggests two converging cell pathways that can be pivotal in the pathogenesis of focal cortical dysplasia and hemimegalencephaly. (J Child Neurol 2005;20:330—336).
Get full access to this article
View all access options for this article.
References
1.
Taylor DC, Falconer MA, Bruton CJ, Corsellis JA: Focal dysplasia of the cerebral cortex in epilepsy. J Neurol Neurosurg Psychiatry1971;34:369—387.
2.
Palmini A., Gambardella A., Andermann F., et al: Intrinsic epileptogenicity of human dysplastic cortex as suggested by corticography and surgical results. Ann Neurol1995;37:476—487.
3.
Flores-Sarnat L.Hemimegalencephaly: Part 1. Genetic, clinical, and imaging aspects. J Child Neurol2002;17:373—384.
4.
Crino PB, Miyata H., Vinters Hvv: Neurodevelopmental disorders as a cause of seizures: Neuropathologic, genetic, and mechanistic considerations. Brain Pathol2002;12:212—233.
5.
Whiting S., Duchowny M.: Clinical spectrum of cortical dysplasia in childhood: Diagnosis and treatment issues. J Child Neurol1999;14:759—771.
6.
Andre VM, Flores-Hernandez J., Cepeda C., et al: NMDA receptor alterations in neurons from pediatric cortical dysplasia tissue. Cereb Cortex2004;14:634—646.
7.
Mischel P., Nguyen LP, Vinters HV: Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathologic features and proposal for a grading system. J Neuropathol Exp Neurol1995;54:137—153.
8.
Barkovich AJ , Kuzniecky RI, Jackson GD, et al: Classification system for malformations of cortical development: Update 2001. Neurology2001;57:2168—2178.
9.
Senol U., Karaali K., Aktekin B., et al: Dizygotic twins with schizencephaly and focal cortical dysplasia . AJNR Am J Neuroradiol2000;21:1520—1521.
10.
Briellmann RS, Jackson GD, Torn-Broers Y., Berkovic SF: Causes of epilepsies: Insights from discordant monozygous twins. Ann Neurol2001;49:45—52.
11.
Becker AJ, Urbach H., Scheffler B., et al: Focal cortical dysplasia of Taylor's balloon cell type: Mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. Ann Neurol2002;52:29—37.
12.
Zhou X., Hampel H., Thiele H., et al: Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet2001;358:210—211.
13.
Zhou XP, Marsh DJ, Hampel H., et al: Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations, and lipomatosis. Hum Mol Genet2000;9:765—768.
14.
Herman TE, Siegel MJ: Hemimegalencephaly and linear nevus sebaceous syndrome. J Perinatol2001;21:336—338.
Galluzzi P., Cerase A., Strambi M., et al: Hemimegalencephaly in tuberous sclerosis complex. J Child Neurol2002;17:677—680.
17.
Crino PB, Dichter MA, Trojanowski JQ, Eberwine J.: Embryonic neuronal markers in tuberous sclerosis: Single cell molecular pathology . Proc Natl Acad Sci U S A 1996;93:14152—14157.
18.
Duong T., De Rosa MJ, Poukens V., et al: Neuronal cytoskeletal abnormalities in human cerebral cortical dysplasia. Acta Neuropathol (Berl)1994 ;87:493—503.
19.
Crino PB, Trojanowski JQ, Eberwine J.: Internexin, MAP1B, and nestin in cortical dysplasia as markers of developmental maturity. Acta Neuropathol (Berl)1997 ;93:619—627.
20.
Crino PB, Duhaime AC, Baltuch G., White R.: Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia. Neurology2001;56:906—913.
21.
White R., Hua Y., Scheithauer B., et al: Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Ann Neurol2001;49:67—78.
22.
Lee A., Maldonado M., Baybis MS, et al: Markers of cellular pro-liferation are expressed in cortical tubers. Ann Neurol2003;53:668—673.
23.
Mizuguchi M. , Yamanouchi H., Becker LE, et al: Doublecortin immunoreactivity in giant cells of tuberous sclerosis and focal cortical dysplasia. Acta Neuropathol (Berl)2002;104:418—424.
24.
Maldonado M. , Baybis M., Newman D., et al: Expression of ICAM-1, TNF-alpha, NFkappaB, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis2003;14:279—290.
25.
Arrazola P. , Hino O., Kobayashi T., et al: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol2002 ;4:699—704.
26.
El-Hashemite N., Zhang H., Henske EP, Kwiatkowski DJ: Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet2003;361:1348—1349.
27.
Inoki K., Li Y., Zhu T.: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling . Nat Cell Biol2002;4:648—657.
28.
Kenerson HL , Aicher LD, True LD, Yeung RS: Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res2002;62:5445—5450.
29.
McManus EJ, Alessi DR: TSC1-TSC2: A complex tale of PKBmediated S6K regulation. Nat Cell Biol2002;4:214—216.
30.
Tee AR, Fingar DC, Manning BD, et al: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling . Proc Natl Acad Sci U S A2002;99:13571—13576.
31.
Onda H., Crino PB, Zhang H., et al: Tsc2 null murine neuronal epithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci2002;21:561—574.
32.
De Rosa MJ, Secor DL, Barsom M., et al: Neuropathologic findings in surgically treated hemimegalencephaly: Immunohistochemical, morphometric, and ultrastructural study. Acta Neuropathol (Berl)1992;84:250—260.
33.
Arai Y., Edwards V., Becker LE: A comparison of cell phenotypes in hemimegalencephaly and tuberous sclerosis . Acta Neuropathol (Berl)1999;98:407—413.
34.
Backman SA, Stambolic V., Suzuki A., et al: Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet2001;29:396—403.
35.
Kwon CH, Zhu X., Zhang J., et al: Pten regulates neuronal soma size: A mouse model of Lhermitte-Duclos disease. Nat Genet2001;29:404—411.
36.
Chenn A., Walsh CA: Regulation of cerebral cortical size by con-trol of cell cycleexit in neural precursors. Science2002;297:365—369.
37.
Chenn A., Walsh CA: Increased neuronal production, enlarged forebrains and cytoarchitectural distortions in beta-catenin over-expressing transgenic mice. Cereb Cortex2003; 13:599-606.
38.
Wodarz A., Nusse R.: Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol1998;14:59—88.
39.
Moon RT, Bowerman B., Boutros M., Perrimon N.: The promise and perils of Wnt signaling through beta-catenin. Science2002;296:1644—1646.
40.
Aberle H., Bauer A., Stappert J., et al: Beta-catenin is a target for the ubiquitin-proteasome pathway . EMBO J1997;163797—3804.
41.
Mak BC, Takemaru K., Kenerson HL, et al: The tuberin-hamartin complex negatively regulates β-catenin signaling activity. J Biol Chem2003;278:5947—5951.
42.
Kacharmina JE, Crino PB, Eberwine J.: Preparation of cDNA from single cells and subcellular regions. Methods Enzymol1999;303:3—18.
43.
Baybis M., Yu J., Lee A., Golden J., Weiner H., McKhann II G., Aronica E., Crino PBMTOR cascade activation distinguishes tubers from focal cortical dysplasia . Ann Neurol2004;56:478-487.
44.
Wingender E. , Chen X., Fricke E., et al: The TRANSFAC system on gene expression regulation. Nucleic Acids Res2001;29:281—283.
45.
Xu L., Corcoran RB, Welsh JW, et al: WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev2000;14:585—595.
46.
Hua Y., Crino PB: Single cell lineage analysis in human focal cortical dysplasia. Cereb Cortex2003;13:693—699.
47.
Miller JR, Hocking AM, Brown JD, Moon RT: Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways. Oncogene1999;18:7860—7872.
48.
Cotter D., Honavar M., Lovestone S., et al: Disturbance of Notch-1 and Wnt signalling proteins in neuroglial balloon cells and abnormal large neurons in focal cortical dysplasia in human cortex. Acta Neuropathol (Berl)1999;98:465—472.
